ecancermedicalscience

Case Report

Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma

24 Nov 2008
T De Pas, G Spitaleri, P Della Vigna, F Toffalorio, G Curigliano, A Gambino, S Boselli, F De Braud

Background: despite the fact that the combination of gemcitabine (GCB) and docetaxel shows an increased benefit for disease-free survival and overall survival compared to GCB alone in patients with soft-tissue sarcoma, GCB mono-chemotherapy should be considered as a preferable option with respect to the combination because of its lower toxicity profile and the possibility of it being administered continuously for a long time period.

Case report: we report a clinical case of a woman with advanced high-grade uterine leiomyosarcoma, refractory to ifosfamide, doxorubicin and trabectedin, who experienced a sustained and progressive response to GCB alone.

Conclusions: GCB given as mono-chemotherapy can obtain long-lasting tumour control in patients heavily pre-treated with various chemotherapeutic regimes for uterine LMS and should be considered as a possible option for this subset of patients.

Keywords:
Gemcitabine; second-line chemotherapy; refractory uterine leiomyosarcoma

Article metrics: 496 views
157
339

Related Articles

Tiago Cordeiro Felismino, Victor Hugo Fonseca de Jesus, Bruno Cezar de Mendonça Uchóa Junior, Francisca Giselle Rocha Moura, Rachel P Riechelmann, Samuel Aguiar Junior, Celso Abdon Lopes de Mello
Małgorzata Sawicka-Żukowska, Włodzimierz Łuczyński, Jakub Dobroch, Maryna Krawczuk-Rybak